Supernus Pharmaceuticals Inc.’s experimental drug for attention deficit hyperactivity disorder (ADHD) met the main goal of a late-stage study in adults.

Skyhawk Therapeutics and Vertex Pharmaceuticals inked a strategic research collaboration and licensing deal focused on developing novel small molecules that modulate RNA splicing.

After touting positive Phase III results at the American Society of Hematology’s annual meeting, the U.S. FDA placed a clinical hold on uniQure”s hemophilia B treatment AMT-061 due to a patient developing liver cancer. 

AstraZeneca and Amgen said their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients’ dependence on steroids, while keeping the respiratory condition in check in a late-stage trial.

France’s Servier bolstered its presence in oncology with the acquisition of the clinical and research-stage oncology business of Agios Pharmaceuticals in a deal worth up to $2 billion.

Tagrisso

The U.S. Food and Drug Administration approved AstraZeneca’s top-selling treatment Tagrisso for another type of lung cancer when diagnosed at an early stage.

Roche

Swiss drugmaker Roche’s experimental eye medicine faricimab matched Bayer and Regeneron’s Eylea against diabetic macular degeneration in acuity gains in two studies, including one in which patients had less-frequent shots.

Takeda

The U.S. Food and Drug Administration approved Takeda Pharmaceutical’s supplemental New Drug Application for Iclusig (ponatinib) for adult patients with chronic-phase chronic myeloid leukemia with resistance or intolerance to at least two prior kinase inhibitors.

Shares of Mesoblast Limited were down more than 30% in trading following the company’s disappointing announcement regarding a stem-cell therapy trial in ventilator-dependent patients with Covid-19 patients who have moderate-to-severe acute respiratory distress syndrome.

Merck

San Diego-based Janux Therapeutics forged a strategic collaboration with pharma giant Merck potentially worth more than $1 billion to develop next-generation T cell engager immunotherapies for the treatment of cancer.